Status | Study |
Not yet recruiting |
Study Name: Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer. Condition: Epithelial Ovarian Cancer Date: 2017-05-13 Interventions: Diagnostic Test: methylation markers screening ctDNA extraction from plasma samples;bisulfite-treated DN |
Not yet recruiting |
Study Name: A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. Condition: Epithelial Ovarian Cancer Date: 2017-03-24 Interventions: Drug: Active Comparator: Olaparib tablets |
Recruiting |
Study Name: Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer Condition: Ovarian Epithelial Cancer Date: 2017-03-04 Interventions: Drug: SPL-108 Subcutaneous injection of 150 mg administered either one time or two times per day. |
Not yet recruiting |
Study Name: Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France Condition: Ovarian Epithelial Cancer Date: 2016-11-28 Interventions: Other: Patient with ovarian epithelial cancer |
Recruiting |
Study Name: REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression Condition: Ovarian Carcinoma Date: 2015-07-29 Interventions: Drug: Tamoxifen Tamoxifen: 40 |
Not yet recruiting |
Study Name: p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer Condition: Ovarian Epithelial Cancer Fallopian Tube Cancer Date: 2015-04-28 Interventions: Drug: p53 gene p53 gene will b |
Completed |
Study Name: Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs. Condition: Epithelial Ovarian Cancer Date: 2014-12-11 Interventions: Other: Gynecological consultation |
Recruiting |
Study Name: Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma Condition: Ovarian Carcinoma Date: 2014-11-19 |
Active, not recruiting |
Study Name: Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) Condition: Ovarian Carcinoma Date: 2014-09-15 Interventions: Device: NovoTTF-100L(O) Patien |
Active, not recruiting |
Study Name: Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma Condition: Ovarian Neoplasms Ovarian Epithelial Cancer Date: 2014-04-04 Interventions: Biological: DCVAC/OvCa with Standard of Care |